https://www.pharmaradar360.com/article/legend-biotech-shares-fall-after-ceo-huang-resigns-533e6c0b1e1415c6Pharma Surgeen2026-07-27T16:03:49.000ZLegend Biotech Shares Fall After CEO Huang Resignshttps://www.pharmaradar360.com/article/branford-based-biotech-quantum-si-at-risk-of-nasdaq-delisting-again-a0ea231be4ae41d7Pharma Surgeen2026-07-27T16:01:47.000ZBranford-based biotech Quantum-Si at risk of Nasdaq delisting, againhttps://www.pharmaradar360.com/article/astrazeneca-pressure-puts-krystal-biotech-tg-therapeutics-and-gilead-stocks-in-f-3b2f99d4be2de9d0Pharma Surgeen2026-07-27T15:58:41.000ZAstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focushttps://www.pharmaradar360.com/article/fda-panel-backs-two-peptides-for-compounding-rejects-one-cd9b092a0e8ed493Pharma Surgeen2026-07-27T15:50:29.000ZFDA Panel Backs Two Peptides For Compounding, Rejects Onehttps://www.pharmaradar360.com/article/apnimed-aspires-for-up-to-160m-ipo-as-sleep-apnea-pill-launch-nears-daa4e90c8f4cbda8Pharma Surgeen2026-07-27T15:30:39.000ZApnimed aspires for up to $160M IPO as sleep apnea pill launch nearshttps://www.pharmaradar360.com/article/american-regent-inc-issues-voluntary-nationwide-recall-of-one-lot-of-papaverine-afa2e9bc60929e90Pharma Surgeen2026-07-27T15:21:49.000ZAmerican Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matterhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-says-nmpa-accepts-new-drug-application-for-sirolimus-for-inj-fbf3c32d41003cfePharma Surgeen2026-07-27T15:17:27.000ZCspc Pharmaceutical Says Nmpa Accepts New Drug Application For Sirolimus For Injection (Albumin-Bound)https://www.pharmaradar360.com/article/capricor-provides-update-on-deramiocel-for-dmd-ahead-of-fda-meeting-86d0682c8f1f1c10Pharma Surgeen2026-07-27T15:11:11.000ZCapricor Provides Update on Deramiocel for DMD Ahead of FDA Meetinghttps://www.pharmaradar360.com/article/finding-light-again-rajminder-s-malhi-journey-527c4ff749a6ca4cPharma Surgeen2026-07-27T15:08:50.000ZFinding Light Again: Rajminder’s Malhi Journeyhttps://www.pharmaradar360.com/article/fda-panel-backs-two-peptides-for-compounding-rejects-one-a13801d41f517795Pharma Surgeen2026-07-27T15:06:18.000ZFDA Panel Backs Two Peptides For Compounding, Rejects Onehttps://www.pharmaradar360.com/article/guidance-ai-airlock-sandbox-phase-2-programme-report-3181fea5f0f98d57Pharma Surgeen2026-07-27T15:02:06.000ZGuidance: AI Airlock Sandbox Phase 2 Programme Reporthttps://www.pharmaradar360.com/article/astrazeneca-s-hsct-tma-drug-misses-main-endpoint-75751e24bd3d64ecPharma Surgeen2026-07-27T14:52:19.000ZAstraZeneca’s HSCT-TMA drug misses main endpointhttps://www.pharmaradar360.com/article/mid-year-check-in-where-is-patient-access-headed-8d82d0c3d1124d87Pharma Surgeen2026-07-27T14:46:02.000ZMid-Year Check-In: Where Is Patient Access Headed?https://www.pharmaradar360.com/article/raymond-james-cuts-legend-biotech-stock-price-target-on-ceo-departure-022dcc6fc11c5b50Pharma Surgeen2026-07-27T14:43:00.000ZRaymond James cuts Legend Biotech stock price target on CEO departurehttps://www.pharmaradar360.com/article/active-biotech-comments-on-first-dose-in-updated-myelofibrosis-study-2c91be58d2f42febPharma Surgeen2026-07-27T14:26:14.000ZActive Biotech comments on first dose in updated myelofibrosis studyhttps://www.pharmaradar360.com/article/innocare-s-oral-tyk2-inhibitor-clears-phase-3-psoriasis-test-2fb74bb689a03d8dPharma Surgeen2026-07-27T14:08:23.000ZInnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis testhttps://www.pharmaradar360.com/article/fbrx-stock-extends-rally-as-barclays-lifts-biotech-hopes-cc4af373a771773fPharma Surgeen2026-07-27T14:02:00.000ZFBRX Stock Extends Rally As Barclays Lifts Biotech Hopeshttps://www.pharmaradar360.com/article/earnings-preview-ono-pharmaceutical-co-ophlf-q1-earnings-expected-to-decline-601bba125e797eeaPharma Surgeen2026-07-27T14:00:13.000ZEarnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Declinehttps://www.pharmaradar360.com/article/why-is-legend-biotech-stock-sliding-today-220d75ccb7dfa839Pharma Surgeen2026-07-27T13:51:45.000ZWhy is Legend Biotech stock sliding today?https://www.pharmaradar360.com/article/pakistan-china-sign-850-million-deals-to-boost-pharmaceutical-cooperation-beecb55001689d92Pharma Surgeen2026-07-27T13:49:24.000ZPakistan, China Sign $850 Million Deals to Boost Pharmaceutical Cooperationhttps://www.pharmaradar360.com/article/cambridge-biotech-taps-external-executive-to-lead-after-elevidys-controversy-64865b2490cedb1fPharma Surgeen2026-07-27T13:39:00.000ZCambridge biotech taps external executive to lead after Elevidys controversyhttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-5ce9d540fae1527cPharma Surgeen2026-07-27T13:34:00.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/legend-biotech-ceo-abruptly-steps-down-without-permanent-replacement-6440a4bdd240d072Pharma Surgeen2026-07-27T13:32:25.000ZLegend Biotech CEO abruptly steps down without permanent replacementhttps://www.pharmaradar360.com/article/from-confidence-to-capital-positioning-biotech-for-the-next-growth-cycle-a33ea444cd0b4b49Pharma Surgeen2026-07-27T13:30:00.000ZFrom confidence to capital: Positioning biotech for the next growth cyclehttps://www.pharmaradar360.com/article/can-takeda-pharmaceutical-tse-4502-trade-at-a-discount-on-new-phase-3-psoriasis-f7b15ea039f4077bPharma Surgeen2026-07-27T13:27:46.000ZCan Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?https://www.pharmaradar360.com/article/pharmalittle-we-re-reading-about-a-u-s-peptide-panel-s-votes-amgen-scuffling-wit-7d9ab943481990f8Pharma Surgeen2026-07-27T13:24:29.000ZPharmalittle: We're reading about a U.S. peptide panel's votes, Amgen scuffling with the FDA, and morehttps://www.pharmaradar360.com/article/crystalys-therapeutics-raises-130-million-series-b-strengthening-fortress-biotec-3ecb209f91aa282aPharma Surgeen2026-07-27T13:16:30.000ZCrystalys Therapeutics Raises $130 Million Series B, Strengthening Fortress Biotech's Dotinurad Stakehttps://www.pharmaradar360.com/article/fda-approves-first-in-class-centanafadine-for-treatment-of-adhd-d2314d6d67029453Pharma Surgeen2026-07-27T13:12:28.000ZFDA Approves First-in-Class Centanafadine for Treatment of ADHDhttps://www.pharmaradar360.com/article/vaccines-are-safe-a-worrisome-portion-of-our-generic-drugs-are-not-7401c9abb3ee1dccPharma Surgeen2026-07-27T13:08:38.000ZVaccines Are Safe. A Worrisome Portion Of Our Generic Drugs Are Nothttps://www.pharmaradar360.com/article/ahead-of-hearing-fda-questions-the-efficacy-of-capricor-s-duchenne-drug-a3ce398a515fc98fPharma Surgeen2026-07-27T13:08:32.000ZAhead of hearing, FDA questions the efficacy of Capricor’s Duchenne drughttps://www.pharmaradar360.com/article/eifo-invests-dkk-20m-in-biotech-firm-quantumcell-a2109e48240dc398Pharma Surgeen2026-07-27T13:02:05.000ZEIFO invests DKK 20m in biotech firm Quantumcellhttps://www.pharmaradar360.com/article/ipo-news-ipo-winners-losers-jersey-mike-s-bubble-baths-and-biotech-wins-abdccdaf61f0b5a3Pharma Surgeen2026-07-27T13:01:21.000ZIPO News - IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Winshttps://www.pharmaradar360.com/article/marco-legal-impulsiona-pesquisa-clinica-e-traz-beneficios-economicos-e-acesso-ma-fec25d391a6a7eecPharma Surgeen2026-07-27T13:00:48.000ZMarco Legal impulsiona pesquisa clínica e traz benefícios econômicos e acesso mais rápido à inovaçãohttps://www.pharmaradar360.com/article/research-bladder-anticholinergics-review-of-risk-of-dementia-57576c29dcc09596Pharma Surgeen2026-07-27T13:00:03.000ZResearch: Bladder Anticholinergics: review of risk of dementiahttps://www.pharmaradar360.com/article/ensuring-drug-quality-mastering-stability-testing-in-pharma-c1ab1302b4326d42Pharma Surgeen2026-07-27T12:54:55.000ZEnsuring drug quality: mastering stability testing in pharmahttps://www.pharmaradar360.com/article/lexicon-s-hcm-study-spans-20-countries-results-anticipated-q1-2027-5864e0682c17b052Pharma Surgeen2026-07-27T12:47:00.000ZLexicon's HCM study spans 20 countries; results anticipated Q1 2027https://www.pharmaradar360.com/article/jyong-biotech-highlights-multi-billion-dollar-global-bph-market-opportunity-and-759397a3febe4786Pharma Surgeen2026-07-27T12:45:28.000ZJyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnershipshttps://www.pharmaradar360.com/article/lexicon-completes-enrollment-in-phase-3-heart-disease-trial-by-investing-com-c85e9dccb2368b58Pharma Surgeen2026-07-27T12:41:45.000ZLexicon completes enrollment in phase 3 heart disease trial By Investing.comhttps://www.pharmaradar360.com/article/boletin-sobre-cosmeticos-biocidas-aemps-y-productos-de-cuidado-personal-abril-ju-fb09e57f98370f43Pharma Surgeen2026-07-27T12:28:01.000ZBoletín sobre Cosméticos, Biocidas AEMPS y Productos de Cuidado Personal. abril-junio 2026https://www.pharmaradar360.com/article/veru-inc-announces-full-enrollment-in-phase-2b-plateau-trial-of-enobosarm-in-old-952522af71603342Pharma Surgeen2026-07-27T12:21:00.000ZVeru Inc. Announces Full Enrollment in Phase 2b PLATEAU Trial of Enobosarm in Older Patients With Obesityhttps://www.pharmaradar360.com/article/oak-hill-bio-and-research-alliance-corporation-iii-announce-business-combination-377cffabc25d59f3Pharma Surgeen2026-07-27T12:19:40.000ZOak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndromehttps://www.pharmaradar360.com/article/aids2026-daily-pill-monthly-pill-six-monthly-jab-why-choice-matters-b9ecf43349b0e9bcPharma Surgeen2026-07-27T12:14:56.000Z#Aids2026: Daily pill. Monthly pill. Six-monthly jab. Why choice mattershttps://www.pharmaradar360.com/article/clinical-trial-per-patient-cost-analytics-for-procurement-and-sponsor-strategy-2f8afe8be649f58ePharma Surgeen2026-07-27T12:12:10.000ZClinical Trial Per-Patient Cost Analytics For Procurement And Sponsor Strategyhttps://www.pharmaradar360.com/article/asia-pacific-roundup-tga-adopts-23-international-scientific-guidelines-5a202994f75b9e91Pharma Surgeen2026-07-27T12:00:00.000ZAsia-Pacific Roundup: TGA adopts 23 international scientific guidelineshttps://www.pharmaradar360.com/article/fortress-biotech-and-subsidiary-urica-therapeutics-announce-crystalys-therapeuti-3f121279fc61a8c8Pharma Surgeen2026-07-27T12:00:00.000ZFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financinghttps://www.pharmaradar360.com/article/strength-seen-in-ono-pharmaceutical-co-ophlf-can-its-9-2-jump-turn-into-more-str-a380a85b11b19294Pharma Surgeen2026-07-27T11:45:00.000ZStrength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?https://www.pharmaradar360.com/article/fda-panel-backs-six-peptides-for-pharmacy-compounding-8548968cf7a9ba5aPharma Surgeen2026-07-27T11:44:22.000ZFDA panel backs six peptides for pharmacy compoundinghttps://www.pharmaradar360.com/article/eikon-therapeutics-doses-first-patient-in-phase-2-3-teluride-008-trial-of-eik100-500f466963f47a9fPharma Surgeen2026-07-27T11:42:00.000ZEikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLChttps://www.pharmaradar360.com/article/wockhardt-gets-us-fda-approval-for-novel-antibiotic-zaynich-29617fae58594a42Pharma Surgeen2026-07-27T11:38:38.000ZWockhardt Gets US FDA Approval for Novel Antibiotic Zaynichhttps://www.pharmaradar360.com/article/eikon-therapeutics-announces-first-patient-dosed-in-teluride-008-a-registrationa-b4c4bb731a6c5752Pharma Surgeen2026-07-27T11:37:52.000ZEikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/eikon-doses-first-patient-in-eik1001-stage-4-lung-cancer-study-7ab8fcf64af0db10Pharma Surgeen2026-07-27T11:30:00.000ZEikon Doses First Patient in EIK1001 Stage 4 Lung Cancer Studyhttps://www.pharmaradar360.com/article/arrowhead-s-rare-cholesterol-disease-study-reaches-70-patients-7652800a87c7864cPharma Surgeen2026-07-27T11:30:00.000ZArrowhead's Rare Cholesterol Disease Study Reaches 70 Patientshttps://www.pharmaradar360.com/article/kelun-biotech-receives-a-clinical-trial-notice-for-its-first-dual-payload-adc-sk-766ee88573f12027Pharma Surgeen2026-07-27T11:30:00.000ZKelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565https://www.pharmaradar360.com/article/fbt-and-ibb-are-not-the-same-biotech-bet-and-5-years-of-returns-prove-it-07945b2a4ab2e4f2Pharma Surgeen2026-07-27T11:25:15.000ZFBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove Ithttps://www.pharmaradar360.com/article/weekly-recap-pelareorep-fda-fast-track-and-nasdaq-sub-1-notice-00d140b5d17702c3Pharma Surgeen2026-07-27T11:25:07.000ZWeekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 noticehttps://www.pharmaradar360.com/article/legend-biotech-legn-announces-ceo-transition-with-interim-leadership-c22abbc49cb63a79Pharma Surgeen2026-07-27T11:16:46.000ZLegend Biotech (LEGN) Announces CEO Transition with Interim Leadershiphttps://www.pharmaradar360.com/article/veraxa-biotech-announces-advancement-of-vxa-222-bispecific-adc-program-in-collab-8560bf89a19ffbddPharma Surgeen2026-07-27T11:13:00.000ZVERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAbhttps://www.pharmaradar360.com/article/okyo-pharma-nasdaq-okyo-plans-phase-3-ncp-trial-joins-btig-conference-75d76cafa23f022dPharma Surgeen2026-07-27T11:00:27.000ZOKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conferencehttps://www.pharmaradar360.com/article/veraxa-s-vxa-222-uses-one-molecule-to-address-two-tumor-antigens-aff976da3555de12Pharma Surgeen2026-07-27T11:00:00.000ZVERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigenshttps://www.pharmaradar360.com/article/okyo-pharma-plans-111-patient-phase-3-corneal-pain-trial-960786616eefabc2Pharma Surgeen2026-07-27T11:00:00.000ZOKYO Pharma plans 111-patient Phase 3 corneal pain trialhttps://www.pharmaradar360.com/article/bnp-paribas-adjusts-pt-on-west-pharmaceutical-services-to-459-from-447-maintains-e5664c0b1768a0c1Pharma Surgeen2026-07-27T10:50:52.000ZBNP Paribas Adjusts PT on West Pharmaceutical Services to $459 From $447, Maintains Outperform Ratinghttps://www.pharmaradar360.com/article/weiss-asset-management-lp-invests-1-99-million-in-west-pharmaceutical-services-i-6a7ecd7c21560beaPharma Surgeen2026-07-27T10:49:51.000ZWeiss Asset Management LP Invests $1.99 Million in West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/argenx-to-pick-up-autoimmune-biotech-forte-biosciences-for-2-2b-5fcd68a86f95712cPharma Surgeen2026-07-27T10:46:00.000ZArgenx to pick up autoimmune biotech Forte Biosciences for $2.2Bhttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-27T10:45:43.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/leadership-changes-at-legend-biotech-legn-576e7777e113ec0aPharma Surgeen2026-07-27T10:44:44.000ZLeadership Changes at Legend Biotech (LEGN)https://www.pharmaradar360.com/article/kura-oncology-reports-encouraging-phase-1a-data-for-darlifarnib-plus-cabozantini-5a7f72aa368d799cPharma Surgeen2026-07-27T10:40:00.000ZKura Oncology Reports Encouraging Phase 1a Data for Darlifarnib Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinomahttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-resigns-5dec7fe994f77283Pharma Surgeen2026-07-27T10:35:15.000ZLegend Biotech CEO Ying Huang Resignshttps://www.pharmaradar360.com/article/kolon-tissuegene-executives-buy-shares-after-clinical-trial-failure-signaling-co-744c742f1691d6aePharma Surgeen2026-07-27T10:35:00.000ZKolon TissueGene Executives Buy Shares After Clinical Trial Failure, Signaling Confidencehttps://www.pharmaradar360.com/article/amazon-filters-eyes-global-pharma-market-at-record-breaking-ispe-singapore-2026-9ce7ba38da96b596Pharma Surgeen2026-07-27T10:34:20.000ZAmazon Filters eyes global pharma market at record-breaking ISPE Singapore 2026https://www.pharmaradar360.com/article/magazine-made-in-the-usa-4a83b14aea62284bPharma Surgeen2026-07-27T10:32:02.000ZMagazine: Made in the USAhttps://www.pharmaradar360.com/article/hbm-holdings-enters-strategic-collaboration-with-china-national-pharmaceutical-g-710ab284c71d9404Pharma Surgeen2026-07-27T10:29:45.000ZHBM Holdings Enters Strategic Collaboration With China National Pharmaceutical Group On Biologics Research And Developmenthttps://www.pharmaradar360.com/article/fda-approves-first-otc-acetaminophen-naproxen-fixed-dose-combination-45a7a511e015ffdcPharma Surgeen2026-07-27T10:29:20.000ZFDA approves first OTC acetaminophen-naproxen fixed-dose combinationhttps://www.pharmaradar360.com/article/cspc-pharmaceutical-expects-h1-2026-profit-attributable-rmb5-9-bln-rmb6-2-bln-78bb458ecfeb50d5Pharma Surgeen2026-07-27T10:26:03.000ZCSPC Pharmaceutical Expects H1 2026 Profit Attributable RMB5.9 Bln–RMB6.2 Blnhttps://www.pharmaradar360.com/article/argenx-pens-2-2bn-deal-to-buy-autoimmune-biotech-forte-ec02e16c0efa48b6Pharma Surgeen2026-07-27T10:23:07.000ZArgenx pens $2.2bn deal to buy autoimmune biotech Fortehttps://www.pharmaradar360.com/article/cspc-pharmaceutical-group-limited-provides-unaudited-consolidated-earnings-guida-f55849fdd080f2c0Pharma Surgeen2026-07-27T10:20:30.000ZCSPC Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2026D Stable Sales Growthhttps://www.pharmaradar360.com/article/thyroid-medication-described-as-subpotent-drug-recalled-by-fda-3e5d147e8b74eca8Pharma Surgeen2026-07-27T10:18:00.000ZThyroid medication described as 'subpotent drug' recalled by FDAhttps://www.pharmaradar360.com/article/outlook-therapeutics-wins-fda-approval-for-lytenava-in-wet-amd-61f9fb2061712f18Pharma Surgeen2026-07-27T10:17:01.000ZOutlook Therapeutics wins FDA approval for Lytenava in wet AMDhttps://www.pharmaradar360.com/article/5-stocks-that-created-fortunes-cmps-327-arwr-222-cgon-148-drts-182-elmd-86-6762879798ba79b6Pharma Surgeen2026-07-27T10:13:00.000Z5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%https://www.pharmaradar360.com/article/legend-biotech-announces-ceo-transition-appoints-alan-bash-interim-chief-executi-cf747abfe7eff102Pharma Surgeen2026-07-27T10:12:00.000ZLegend Biotech Announces CEO Transition, Appoints Alan Bash Interim Chief Executive Officerhttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-steps-down-alan-bash-named-interim-6c6b428239efe1a9Pharma Surgeen2026-07-27T10:11:12.000ZLegend Biotech CEO Ying Huang steps down, Alan Bash named interimhttps://www.pharmaradar360.com/article/argenx-acquires-forte-for-2-2b-to-get-hands-on-phase-2-stage-vitiligo-drug-ee4a99cef64fae7cPharma Surgeen2026-07-27T10:08:15.000ZArgenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drughttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-steps-down-alan-bash-named-interim-aa272bb9fe0e6b7fPharma Surgeen2026-07-27T10:07:45.000ZLegend Biotech CEO Ying Huang steps down, Alan Bash named interimhttps://www.pharmaradar360.com/article/legend-biotech-legn-ceo-ying-huang-exits-as-board-appoints-interim-chief-7512a9223f8f60f9Pharma Surgeen2026-07-27T10:03:04.000ZLegend Biotech (LEGN) CEO Ying Huang exits as board appoints interim chiefhttps://www.pharmaradar360.com/article/legend-biotech-announces-ceo-transition-2836d2c166c2516bPharma Surgeen2026-07-27T10:00:00.000ZLegend Biotech Announces CEO Transitionhttps://www.pharmaradar360.com/article/legend-biotech-ceo-ying-huang-steps-down-search-begins-baebdb1f6466479cPharma Surgeen2026-07-27T10:00:00.000ZLegend Biotech CEO Ying Huang Steps Down; Search Beginshttps://www.pharmaradar360.com/article/puerto-rico-imports-3-254-billion-in-generic-drugs-and-faces-the-threat-of-tarif-af65b7b284f2ca8dPharma Surgeen2026-07-27T10:00:00.000ZPuerto Rico imports $3.254 billion in generic drugs and faces the threat of tariffs of up to 200%https://www.pharmaradar360.com/article/trialblazer-vs-australia-why-u-s-biotech-regulation-is-slow-1-3776a41e2574a657Pharma Surgeen2026-07-27T10:00:00.000ZTrialBlazer vs. Australia_ Why U.S. Biotech Regulation is Slow(1)https://www.pharmaradar360.com/article/takeda-pharmaceutical-co-tak-shares-purchased-by-renaissance-technologies-llc-1b90d613ad707d25Pharma Surgeen2026-07-27T09:49:56.000ZTakeda Pharmaceutical Co. $TAK Shares Purchased by Renaissance Technologies LLChttps://www.pharmaradar360.com/article/working-for-ukhsa-b7a5672bf6c8e205Pharma Surgeen2026-07-27T09:47:20.000ZWorking for UKHSAhttps://www.pharmaradar360.com/article/renaissance-technologies-llc-has-52-55-million-stock-position-in-west-pharmaceut-d8f18be42c337273Pharma Surgeen2026-07-27T09:45:53.000ZRenaissance Technologies LLC Has $52.55 Million Stock Position in West Pharmaceutical Services, Inc. $WSThttps://www.pharmaradar360.com/article/rfk-jr-s-big-promise-to-ban-pharmaceutical-ads-is-in-the-slow-lane-74b6b1a818323117Pharma Surgeen2026-07-27T09:38:43.000ZRFK Jr.’s Big Promise to Ban Pharmaceutical Ads Is in the Slow Lanehttps://www.pharmaradar360.com/article/pharma-packaging-under-ppwr-safety-and-validation-demands-challenge-compliance-18bc7bd4deddc738Pharma Surgeen2026-07-27T09:28:34.000ZPharma packaging under PPWR: Safety and validation demands challenge compliancehttps://www.pharmaradar360.com/article/from-a-small-town-pledge-to-the-big-time-a-quest-to-turn-central-ohio-into-a-bio-8cbd9cdf7a50e1acPharma Surgeen2026-07-27T09:19:39.000ZFrom a small-town pledge to the big time: A quest to turn central Ohio into a biotech hubhttps://www.pharmaradar360.com/article/sei-investments-co-has-35-62-million-position-in-teva-pharmaceutical-industries-6b6d12f9a699d7eaPharma Surgeen2026-07-27T09:16:14.000ZSei Investments Co. Has $35.62 Million Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/click-e-stock-samsung-epis-holdings-focus-on-new-drug-development-strategy-over-8a5daa69df0418f5Pharma Surgeen2026-07-27T08:55:00.000Z[Click e-Stock] "Samsung Epis Holdings: Focus on New Drug Development Strategy Over Short-Term Earnings... Target Price Lowered"https://www.pharmaradar360.com/article/benefiting-from-chinese-pharma-innovation-04277890893b0413Pharma Surgeen2026-07-27T08:49:09.000ZBenefiting from Chinese pharma innovationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-62f452371af74327Pharma Surgeen2026-07-27T08:48:41.000ZDHSC: workforce management informationhttps://www.pharmaradar360.com/article/dhsc-workforce-management-information-june-2026-794c237d7da5718fPharma Surgeen2026-07-27T08:48:02.000ZDHSC: workforce management information June 2026https://www.pharmaradar360.com/article/compounded-glp-1-drugs-creating-concern-among-doctors-and-fda-eab8401f51842b27Pharma Surgeen2026-07-27T08:38:20.000ZCompounded GLP-1 drugs creating concern among doctors and FDAhttps://www.pharmaradar360.com/article/the-intelligent-laboratory-how-ai-automation-digital-science-are-transforming-ph-18f02e0c108ac326Pharma Surgeen2026-07-27T08:21:44.000ZThe Intelligent Laboratory: How AI, Automation & Digital Science Are Transforming Pharmaceutical Qualityhttps://www.pharmaradar360.com/article/zentalis-azenosertib-a-calculated-wager-on-a-dual-track-path-to-ovarian-cancer-a-d1d28ccfca3d78fbPharma Surgeen2026-07-27T08:21:05.000ZZentalis' Azenosertib: A Calculated Wager on a Dual-Track Path to Ovarian Cancer Approvalhttps://www.pharmaradar360.com/article/korea-selects-manager-for-170-bil-phase-3-fund-moves-closer-to-1-tri-bio-megafun-e9a3e09b821aecc8Pharma Surgeen2026-07-27T08:19:45.000ZKorea selects manager for ₩170 bil. phase 3 fund, moves closer to ₩1 tri. bio megafundhttps://www.pharmaradar360.com/article/astrazeneca-achieves-revenues-of-15-4-billion-dollars-supported-by-the-growth-in-90a059b22372aa48Pharma Surgeen2026-07-27T08:19:36.000ZAstraZeneca achieves revenues of 15.4 billion dollars supported by the growth in pharmaceutical saleshttps://www.pharmaradar360.com/article/north-west-university-training-future-experts-in-pharmaceutical-sciences-cca3e5439967544bPharma Surgeen2026-07-27T08:18:53.000ZNorth-West University: Training future experts in pharmaceutical scienceshttps://www.pharmaradar360.com/article/2026-787608f8eb716b96Pharma Surgeen2026-07-27T08:16:31.000ZΓενόσημα Μαΐου 2026 _ Προτεινόμενες Τιμές προς Διαβούλευσηhttps://www.pharmaradar360.com/article/aribio-and-forevernk-join-to-develop-next-gen-alzheimer-s-drugs-in-south-korea-c-b2995e50edaf6264Pharma Surgeen2026-07-27T08:13:00.000ZAribio and ForeverNK join to develop next-gen Alzheimer’s drugs in South Korea - CHOSUNBIZhttps://www.pharmaradar360.com/article/the-next-generation-of-pharmaceutical-blister-packs-8bfe5a8b79b279a2Pharma Surgeen2026-07-27T08:06:41.000ZThe next generation of pharmaceutical blister packshttps://www.pharmaradar360.com/article/first-aid-how-to-make-pension-funds-pay-for-biotech-1c17a4e10b3dc50ePharma Surgeen2026-07-27T07:47:11.000ZFIRST AID: How to make pension funds pay for Biotechhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-company-limited-tak-stock-price-news-quote-and-history-f6907d9cbe0672a9Pharma Surgeen2026-07-27T07:44:28.000ZTakeda Pharmaceutical Company Limited (TAK) stock price, news, quote and historyhttps://www.pharmaradar360.com/article/stopped-the-six-year-cost-of-trials-that-never-reached-the-finish-line-da3c16a87362ec33Pharma Surgeen2026-07-27T07:44:11.000ZStopped: The Six-Year Cost of Trials That Never Reached the Finish Linehttps://www.pharmaradar360.com/article/dimerix-asx-dxb-adds-a-phase-2-asset-and-secures-a-new-us-patent-has-its-biotech-f4dff9ac0958d53ePharma Surgeen2026-07-27T07:40:00.000ZDimerix (ASX:DXB) Adds a Phase 2 Asset and Secures a New US Patent—Has Its Biotech Pipeline Just Been Transformed?https://www.pharmaradar360.com/article/astrazeneca-s-q2-net-profit-hits-2-5b-amid-fallout-from-wainua-clinical-trial-fa-276820c8c2c4c7f0Pharma Surgeen2026-07-27T07:39:34.000ZAstraZeneca’s Q2 Net Profit Hits $2.5B Amid Fallout From Wainua Clinical Trial Failurehttps://www.pharmaradar360.com/article/korea-selects-manager-for-170-bil-phase-3-fund-moves-closer-to-1-tri-bio-megafun-4b5f37db56af7520Pharma Surgeen2026-07-27T07:22:46.000ZKorea selects manager for ₩170 bil. phase 3 fund, moves closer to ₩1 tri. bio megafundhttps://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-31-report-data-to-week-30-26-july-2-382af7c5ca707f23Pharma Surgeen2026-07-27T07:18:18.000ZNational Norovirus and Rotavirus Report, week 31 report: data to week 30 (26 July 2026)https://www.pharmaradar360.com/article/the-small-cap-wrap-quarterlies-acquisitions-and-biotech-breakthroughs-9d6e1e4f86f2a32fPharma Surgeen2026-07-27T07:13:50.000ZThe Small Cap Wrap: Quarterlies, acquisitions and biotech breakthroughshttps://www.pharmaradar360.com/article/ucl-kenya-secures-landmark-merck-hiv-prevention-pill-deal-f45e8f93e88b67dfPharma Surgeen2026-07-27T07:08:37.000ZUCL Kenya Secures Landmark Merck HIV Prevention Pill Dealhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-31-report-data-to-week-30-dat-a3fb4f87cd2afcf2Pharma Surgeen2026-07-27T07:04:24.000ZNational flu and COVID-19 surveillance report, week 31 report: data to week 30 (data up to 26 July 2026)https://www.pharmaradar360.com/article/denmark-s-foundation-fueled-biotech-boom-redraws-the-nordic-map-cf871b13881163f4Pharma Surgeen2026-07-27T07:04:19.000ZDenmark’s foundation‑fueled biotech boom redraws the Nordic maphttps://www.pharmaradar360.com/article/digital-and-intelligent-health-forum-wang-zunlong-building-new-benchmark-for-med-7d15031c5494f955Pharma Surgeen2026-07-27T07:02:24.000ZDigital and Intelligent Health Forum｜Wang Zunlong: Building new benchmark for medical data, AI integration in Xi'anhttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-d6972347e5f20166Pharma Surgeen2026-07-27T06:57:59.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/argenx-to-acquire-forte-biosciences-for-2-2-billion-gains-fb102-antibody-6c77f73490b846a6Pharma Surgeen2026-07-27T06:50:53.000Zargenx to Acquire Forte Biosciences for $2.2 Billion, Gains FB102 Antibodyhttps://www.pharmaradar360.com/article/the-oral-revolution-in-inflammatory-skin-disease-what-povorcitinib-s-phase-3-des-5b6495fc290e8d44Pharma Surgeen2026-07-27T06:50:53.000ZThe Oral Revolution in Inflammatory Skin Disease: What Povorcitinib’s Phase 3 Design Reveals About the Next Wave of Dermatology Trialshttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-3c1e545ea0c4b0dePharma Surgeen2026-07-27T06:33:00.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/pharmacyte-biotech-inc-pmcb-earnings-forecast-future-eps-revenue-growth-estimate-5e5d0b550fe0d746Pharma Surgeen2026-07-27T06:27:18.000ZPharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimateshttps://www.pharmaradar360.com/article/4519-t-fy2026-q2-earnings-call-chugai-pharmaceutical-q2-core-operating-profit-ri-60b871b288c379c8Pharma Surgeen2026-07-27T06:16:00.000Z[4519.T FY2026 Q2 Earnings Call] Chugai Pharmaceutical Q2 Core Operating Profit Rises 21% to ¥329.1 Billion as Overseas Blockbusters and New Drug Royalties Diversify Revenue Structurehttps://www.pharmaradar360.com/article/update-on-phase-iii-trial-of-ultomiris-in-adults-and-adolescents-with-thrombotic-643bcc52602696c6Pharma Surgeen2026-07-27T06:10:00.000ZUpdate on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplanthttps://www.pharmaradar360.com/article/korea-investment-partners-chosen-to-manage-phase-3-trial-fund-targeting-150-bill-6a2f1b2929204739Pharma Surgeen2026-07-27T06:07:31.000ZKorea Investment Partners Chosen to Manage 'Phase 3 Trial Fund' Targeting 150 Billion Wonhttps://www.pharmaradar360.com/article/sonesitatug-vedotin-demonstrated-a-statistically-significant-and-highly-clinical-ea4cccceba4843c6Pharma Surgeen2026-07-27T06:05:00.000ZSonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancershttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-f38dcdd85eaaae80Pharma Surgeen2026-07-27T05:56:00.000ZChinese Biotech Overtakes AI as Emerging-Market Growth Tradehttps://www.pharmaradar360.com/article/kolon-tissuegene-officially-apologized-to-shareholders-for-failing-to-achieve-it-75fd6ed6768bb82cPharma Surgeen2026-07-27T05:53:52.000ZKolon TissueGene officially apologized to shareholders for failing to achieve its goal in the firsthttps://www.pharmaradar360.com/article/cha-biotech-wins-1-7-mil-government-ai-project-for-cell-therapy-documentation-b0e60bd45cc6f33fPharma Surgeen2026-07-27T05:23:40.000ZCHA Biotech wins $1.7 mil. government AI project for cell therapy documentationhttps://www.pharmaradar360.com/article/etf-showdown-xbi-vs-pbe-which-biotech-fund-wins-eaa983bcff893e4cPharma Surgeen2026-07-27T05:00:55.000ZETF Showdown: XBI vs PBE, Which Biotech Fund Wins?https://www.pharmaradar360.com/article/la-aemps-primera-agencia-europea-que-participa-en-un-programa-de-pasantias-inter-ab34068b38aff1ddPharma Surgeen2026-07-27T05:00:40.000ZLa AEMPS, primera agencia europea que participa en un programa de pasantías internacionales con la Organización Panamericana de la Saludhttps://www.pharmaradar360.com/article/otsuka-receives-fda-approval-for-first-in-class-simtriyo-centanafadine-for-the-t-c33d573214541ac9Pharma Surgeen2026-07-27T04:59:30.000ZOtsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Olderhttps://www.pharmaradar360.com/article/k-bio-1-trillion-mega-fund-imminent-first-ever-phase-3-clinical-trial-fund-launc-bdcb6522e293e8b7Pharma Surgeen2026-07-27T04:47:00.000ZK-Bio 1 Trillion Mega Fund 'Imminent', 'First-Ever' Phase 3 Clinical Trial Fund Launch! : 경제 : JKNhttps://www.pharmaradar360.com/article/washington-house-passes-fda-bill-to-move-medicine-testing-beyond-animals-bd99d3e7ceba2056Pharma Surgeen2026-07-27T04:32:00.000ZWashington House passes FDA bill to move medicine testing beyond animalshttps://www.pharmaradar360.com/article/zhejiang-huakang-pharmaceutical-co-ltd-class-a-revenue-breakdown-sse-605077-95ead1ee67ac300cPharma Surgeen2026-07-27T04:19:18.000ZZhejiang Huakang Pharmaceutical Co., Ltd. Class A Revenue Breakdown – SSE:605077https://www.pharmaradar360.com/article/summit-merck-must-navigate-new-regulatory-terrain-in-china-first-cancer-landscap-cd45c263b6971f8dPharma Surgeen2026-07-27T04:10:37.000ZSummit, Merck must navigate new regulatory terrain in China-first cancer landscapehttps://www.pharmaradar360.com/article/lilly-abbvie-climb-aboard-in-vivo-car-t-train-but-safety-remains-a-hurdle-23c04a273cf96888Pharma Surgeen2026-07-27T04:04:03.000ZLilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdlehttps://www.pharmaradar360.com/article/p840k-unregistered-cooking-oil-seized-in-pampanga-cidg-raids-san-fernando-shop-o-020ed2822fd3419ePharma Surgeen2026-07-27T03:26:53.000ZP840K Unregistered Cooking Oil Seized in Pampanga: CIDG Raids San Fernando Shop Over FDA Law Violationshttps://www.pharmaradar360.com/article/how-new-phase-3-psoriasis-data-for-zasocitinib-at-takeda-pharmaceutical-tse-4502-4af123f3399138eaPharma Surgeen2026-07-27T03:16:00.000ZHow New Phase 3 Psoriasis Data For Zasocitinib At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Storyhttps://www.pharmaradar360.com/article/chinese-biotech-overtakes-ai-as-emerging-market-growth-trade-4ddc4205b8e60898Pharma Surgeen2026-07-27T03:08:00.000ZChinese biotech overtakes AI as emerging-market growth tradehttps://www.pharmaradar360.com/article/ibrx-stock-rises-overnight-retail-traders-hunt-for-global-expansion-clues-ahead-2c3156530805b6a5Pharma Surgeen2026-07-27T03:00:00.000ZIBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conferencehttps://www.pharmaradar360.com/article/south-korea-taps-korea-investment-partners-to-launch-phase-3-trial-fund-chosunbi-df2b48106ae93a4fPharma Surgeen2026-07-27T03:00:00.000ZSouth Korea taps Korea Investment Partners to launch phase 3 trial fund - CHOSUNBIZhttps://www.pharmaradar360.com/article/korea-investment-partners-selected-as-manager-for-korea-s-first-phase-3-clinical-0ebfff5063169a52Pharma Surgeen2026-07-27T03:00:00.000ZKorea Investment Partners Selected as Manager for Korea's First 'Phase 3 Clinical Trial Specialized Fund'https://www.pharmaradar360.com/article/fda-advisory-no-2026-0809-public-health-warning-against-the-purchase-and-use-of-4e2d4c9ba3daceefPharma Surgeen2026-07-27T02:47:39.000ZFDA Advisory No.2026-0809 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Methyl Salicylate + Menthol + Camphor Natural Green Leaf Lose Pain Topical Analgesic 20g” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/fda-advisory-no-2026-0805-public-health-warning-against-the-purchase-and-use-of-202961e5201e38fePharma Surgeen2026-07-27T02:32:01.000ZFDA Advisory No.2026-0805 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “OTC Natural Green Leaf Anti-Itch Cream 20g” - Food and Drug Administrationhttps://www.pharmaradar360.com/article/interview-the-eu-s-biotech-act-is-helpful-but-not-yet-the-solution-investors-say-a34caed5b005aa02Pharma Surgeen2026-07-27T02:26:46.000ZINTERVIEW: 'The EU’s Biotech Act is helpful, but not yet the solution,' investors sayhttps://www.pharmaradar360.com/article/hk-inno-n-s-k-cab-gains-ulcer-prevention-indication-achieving-six-p-cab-approval-4531603ab2bc4d3cPharma Surgeen2026-07-27T02:26:00.000ZHK inno.N's K-CAB Gains Ulcer Prevention Indication, Achieving Six P-CAB Approvals in South Koreahttps://www.pharmaradar360.com/article/fda-advisers-recommend-relaxing-us-rules-on-compounding-peptides-33818127deaf2bdcPharma Surgeen2026-07-27T02:10:41.000ZFDA advisers recommend relaxing US rules on compounding peptideshttps://www.pharmaradar360.com/article/otsuka-launches-pocari-sweat-ion-water-powder-stick-packet-to-make-500mleasy-wat-f9bcdda90a05ff88Pharma Surgeen2026-07-27T02:00:00.000ZOtsuka Launches POCARI SWEAT ION WATER Powder Stick Packet to Make 500mlEasy Water and Ion Replenishment for Day-to-Day Situations: Ideal for Use with Reusable Bottleshttps://www.pharmaradar360.com/article/hlb-pep-registers-antidiuretic-hormone-api-with-u-s-fda-c177529d79b76812Pharma Surgeen2026-07-27T01:02:39.000ZHLB Pep Registers Antidiuretic Hormone API with U.S. FDAhttps://www.pharmaradar360.com/article/gc-biopharma-files-for-phase-2-trial-of-covid-19-mrna-vaccine-targets-2028-appro-3cfb88e87175b8abPharma Surgeen2026-07-27T00:52:50.000ZGC Biopharma Files for Phase 2 Trial of COVID-19 mRNA Vaccine, Targets 2028 Approvalhttps://www.pharmaradar360.com/article/kolon-tissuegene-rebounds-as-investors-bet-phase-3-setback-priced-in-chosunbiz-ab3d382446c50f5ePharma Surgeen2026-07-27T00:52:00.000ZKolon TissueGene rebounds as investors bet phase 3 setback priced in - CHOSUNBIZhttps://www.pharmaradar360.com/article/chinese-biotech-is-stealing-the-emerging-market-trade-that-ai-dominated-for-two-26346641454d4999Pharma Surgeen2026-07-27T00:14:27.000ZChinese biotech is stealing the emerging market trade that AI dominated for two yearshttps://www.pharmaradar360.com/article/gc-green-cross-submits-ind-for-phase-2-clinical-trial-of-covid-19-mrna-vaccine-s-d25eb3c88b69e98dPharma Surgeen2026-07-27T00:07:36.000ZGC Green Cross Submits IND for Phase 2 Clinical Trial of COVID-19 mRNA Vaccine...Selected for Disease Control Agency Support Projecthttps://www.pharmaradar360.com/article/hk-inno-n-wins-sixth-k-cab-indication-leading-south-korea-s-p-cab-field-chosunbi-05fd70c25c27238bPharma Surgeen2026-07-27T00:03:00.000ZHK inno.N wins sixth K-CAB indication, leading South Korea’s P-CAB field - CHOSUNBIZhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-ff3d167da94fa807Pharma Surgeen2026-07-27T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/novo-nordisk-filed-form-6-k-61c28a8b6e025cb8Pharma Surgeen2026-07-27T00:00:00.000ZNovo Nordisk filed Form 6-Khttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-88027fda4653c0eaPharma Surgeen2026-07-27T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/otsuka-receives-fda-approval-for-first-in-class-simtriyo-centanafadine-for-the-t-34e7938624abe63aPharma Surgeen2026-07-27T00:00:00.000ZOtsuka Receives FDA Approval for First-in-Class SIMTRIYO (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Olderhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-65492df36614037aPharma Surgeen2026-07-27T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-f5d308fbb3ec7554Pharma Surgeen2026-07-27T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-1745d9ee93ef5ad6Pharma Surgeen2026-07-27T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-ee838d2227a73a4dPharma Surgeen2026-07-27T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-07d221ad2234d9f2Pharma Surgeen2026-07-27T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-7d8f7475fe865f1dPharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-c6e197a0da6f8286Pharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-3b145c4c404c04bdPharma Surgeen2026-07-27T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-801444e85d384093Pharma Surgeen2026-07-27T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-5e6ef0e88a69ce16Pharma Surgeen2026-07-27T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-be5008e326271f88Pharma Surgeen2026-07-27T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-4161b618e4f03249Pharma Surgeen2026-07-27T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-5ed6ae332bb7ae6aPharma Surgeen2026-07-27T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e254bdeaee59cf23Pharma Surgeen2026-07-27T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-03e180a51f4945d0Pharma Surgeen2026-07-27T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-quarterly-listing-of-program-issuances-april-thro-abab6c91c8e83f88Pharma Surgeen2026-07-27T00:00:00.000ZMedicare and Medicaid Programs; Quarterly Listing of Program Issuances-April Through June 2026https://www.pharmaradar360.com/article/medicare-program-approved-renewal-of-deeming-authority-of-the-national-committee-a630dfc206cf5813Pharma Surgeen2026-07-27T00:00:00.000ZMedicare Program; Approved Renewal of Deeming Authority of the National Committee for Quality Assurance (NCQA) for Medicare Advantage Health Maintenance Organizations and Preferred Provider Organizationshttps://www.pharmaradar360.com/article/proposed-information-collection-activity-mental-health-assessment-form-and-onsit-f26ea386d7cc7efcPharma Surgeen2026-07-27T00:00:00.000ZProposed Information Collection Activity; Mental Health Assessment Form and Onsite Health Intervention Formhttps://www.pharmaradar360.com/article/proposed-data-collection-submitted-for-public-comment-and-recommendations-6cac63d3395a9408Pharma Surgeen2026-07-27T00:00:00.000ZProposed Data Collection Submitted for Public Comment and Recommendationshttps://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-855dbe1d11f97a88Pharma Surgeen2026-07-27T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-a07a07a2e6a10cf7Pharma Surgeen2026-07-27T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Active Noise Attenuation System for Infant Incubatorshttps://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-non-medic-c008d0c28d80785aPharma Surgeen2026-07-27T00:00:00.000ZMedical Devices; Gastroenterology-Urology Devices; Classification of the Non-Medicated Topical Formulation for Treatment of Erectile Dysfunctionhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-6a9fe8ab160a10edPharma Surgeen2026-07-27T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Radioactive Drug Research Committeeshttps://www.pharmaradar360.com/article/otsuka-to-present-pivotal-two-year-egfr-results-from-the-phase-3-visionary-trial-0090d847504d947cPharma Surgeen2026-07-27T00:00:00.000ZOtsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026（Link to Otsuka America Pharmaceutical website）https://www.pharmaradar360.com/article/cleveland-clinic-establishes-center-for-trauma-9d3b5475db9a288aPharma Surgeen2026-07-27T00:00:00.000ZCleveland Clinic Establishes Center for Traumahttps://www.pharmaradar360.com/article/vaginal-estrogen-application-techniques-for-prevention-of-urinary-tract-infectio-648f406cf56d041ePharma Surgeen2026-07-27T00:00:00.000ZVaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection: A Randomized Trial.https://www.pharmaradar360.com/article/impact-of-international-travel-on-clinical-outcomes-of-mpox-cases-in-jeddah-saud-bfe9ce158b293109Pharma Surgeen2026-07-27T00:00:00.000ZImpact of International Travel on Clinical Outcomes of Mpox Cases in Jeddah, Saudi Arabia: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/allopurinol-induced-drug-reaction-with-eosinophilia-and-systemic-symptoms-dress-f60ff0c089b9ceefPharma Surgeen2026-07-27T00:00:00.000ZAllopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Case Report and Review of the Published Evidence From Indiahttps://www.pharmaradar360.com/article/evaluation-of-the-dietary-quality-of-selected-public-university-and-private-hosp-615a6e4b513bc756Pharma Surgeen2026-07-27T00:00:00.000ZEvaluation of the dietary quality of selected public, university, and private hospital menushttps://www.pharmaradar360.com/article/anaphylaxis-in-a-tertiary-care-center-clinical-characteristics-management-gaps-a-4d040dd0ff185534Pharma Surgeen2026-07-27T00:00:00.000ZAnaphylaxis in a Tertiary Care Center: Clinical characteristics, management gaps, and opportunities for improving patient carehttps://www.pharmaradar360.com/article/the-effectiveness-of-electric-and-manual-toothbrush-use-on-the-loe-and-silness-p-3307196a36e2951dPharma Surgeen2026-07-27T00:00:00.000ZThe Effectiveness of Electric and Manual Toothbrush Use on the Loe and Silness Plaque Index Among Students with Intellectual Disabilities at SLBN Branjangan Jember, East Java, Indonesiahttps://www.pharmaradar360.com/article/colonic-perforation-secondary-to-entamoeba-histolytica-infection-a-case-report-a7a3e0e672b11e98Pharma Surgeen2026-07-27T00:00:00.000ZColonic Perforation Secondary to Entamoeba Histolytica Infection: A Case Reporthttps://www.pharmaradar360.com/article/the-viral-legacy-in-diabetic-ketoacidosis-impact-of-concurrent-respiratory-viral-b889283e836c26bePharma Surgeen2026-07-27T00:00:00.000ZThe Viral Legacy in Diabetic Ketoacidosis: Impact of Concurrent Respiratory Viral Infections on Acute Severity and Long-Term Glycemic Control in Children With Newly Diagnosed Type 1 Diabeteshttps://www.pharmaradar360.com/article/digital-intervention-for-household-drug-management-impacts-on-knowledge-attitude-1439596d30eac1e5Pharma Surgeen2026-07-27T00:00:00.000ZDigital intervention for household drug management: Impacts on knowledge, attitudes, practices, and economic losseshttps://www.pharmaradar360.com/article/identifying-the-critical-window-and-adiposity-trap-in-spanish-children-longitudi-c9715844fb10aaabPharma Surgeen2026-07-27T00:00:00.000ZIdentifying the Critical Window and Adiposity Trap in Spanish Children: Longitudinal Evolution and Transition Probabilities of BMI Z-Scores from a Clinical Registry (2021–2026)https://www.pharmaradar360.com/article/fixed-prosthetic-restorations-and-periodontal-health-from-fabrication-to-supracr-dac7e387998c7f13Pharma Surgeen2026-07-27T00:00:00.000ZFixed Prosthetic Restorations and Periodontal Health: From Fabrication to Supracrestal Tissue Attachment Preservation and Clinical Outcomeshttps://www.pharmaradar360.com/article/effectiveness-of-diosmin-cumarin-and-arbutin-in-reducing-edema-and-pain-after-hi-366ffde223cbd4b1Pharma Surgeen2026-07-27T00:00:00.000ZEffectiveness of Diosmin, Cumarin and Arbutin in Reducing Edema and Pain After Hip or Knee Arthroplastyhttps://www.pharmaradar360.com/article/biliary-reconstruction-in-liver-transplantation-for-primary-sclerosing-cholangit-4d2b6d90d65b3322Pharma Surgeen2026-07-27T00:00:00.000ZBiliary Reconstruction in Liver Transplantation for Primary Sclerosing Cholangitis: Outcomes of an Anatomy-Driven Shift Towards Duct-to-Duct Anastomosishttps://www.pharmaradar360.com/article/postpartum-depressive-symptoms-among-women-with-elevated-prenatal-anxiety-in-kaz-624fab844f924164Pharma Surgeen2026-07-27T00:00:00.000ZPostpartum Depressive Symptoms Among Women with Elevated Prenatal Anxiety in Kazakhstan: Prospective Observational Cohort Studyhttps://www.pharmaradar360.com/article/pulsed-field-ablation-for-atrial-fibrillation-in-obesity-reassessing-risk-safety-2ae60bc0f3b5451cPharma Surgeen2026-07-27T00:00:00.000ZPulsed Field Ablation for Atrial Fibrillation in Obesity: Reassessing Risk, Safety, and Successhttps://www.pharmaradar360.com/article/association-of-general-anesthesia-exposure-with-cognitive-outcomes-in-older-adul-9b713d75d1b8d760Pharma Surgeen2026-07-27T00:00:00.000ZAssociation of General Anesthesia Exposure with Cognitive Outcomes in Older Adults: A Cross-Sectional Study in a Korean Cohorthttps://www.pharmaradar360.com/article/comparison-of-the-effect-of-pyridostigmine-and-sugammadex-on-emergence-delirium-491c37e8c02e46f0Pharma Surgeen2026-07-27T00:00:00.000ZComparison of the Effect of Pyridostigmine and Sugammadex on Emergence Delirium in Pediatric Patients Undergoing Strabismus Surgery: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/self-reported-neck-and-low-back-disability-in-female-show-jumping-riders-a-cross-18bc811e9b0d3fdcPharma Surgeen2026-07-27T00:00:00.000ZSelf-Reported Neck and Low Back Disability in Female Show Jumping Riders: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/circulating-thioredoxin-1-as-an-adjunct-to-mammography-for-breast-cancer-detecti-29cc158708193eefPharma Surgeen2026-07-27T00:00:00.000ZCirculating Thioredoxin 1 as an Adjunct to Mammography for Breast Cancer Detection: A Multicenter Clinical Validation Studyhttps://www.pharmaradar360.com/article/complicated-versus-uncomplicated-acute-appendicitis-clinical-characteristics-dia-5c211b3e64a429b1Pharma Surgeen2026-07-27T00:00:00.000ZComplicated versus uncomplicated acute appendicitis: clinical characteristics, diagnostic scores, surgical management, and outcomes in a tertiary hospital in Mogadishu, Somaliahttps://www.pharmaradar360.com/article/development-and-validation-of-a-clinical-predictive-model-for-the-risk-of-recurr-afb0f1089390c6edPharma Surgeen2026-07-27T00:00:00.000ZDevelopment and validation of a clinical predictive model for the risk of recurrence after unilateral biportal endoscopic diskectomyhttps://www.pharmaradar360.com/article/cohort-profile-guangdong-pharmaceutical-university-occupational-health-cohort-in-14213c93414532adPharma Surgeen2026-07-27T00:00:00.000ZCohort profile: Guangdong Pharmaceutical University Occupational Health Cohort in Xishan Coal Electricity Group (GDPU-OHC)https://www.pharmaradar360.com/article/stathmin-in-human-health-and-diseases-from-cytoskeletal-dynamics-to-clinical-imp-e5b9df1c3a674330Pharma Surgeen2026-07-27T00:00:00.000ZStathmin in human health and diseases: from cytoskeletal dynamics to clinical implicationshttps://www.pharmaradar360.com/article/a-full-cycle-integrated-management-model-for-esophageal-cancer-in-county-health-5e49719e86ea4e6aPharma Surgeen2026-07-27T00:00:00.000ZA full-cycle integrated management model for esophageal cancer in county health systems: effects on care processes, clinical outcomes, quality of life, and cost-utilityhttps://www.pharmaradar360.com/article/effects-of-aged-black-garlic-abg10-on-lipoprotein-subclass-composition-in-grade-49f256dbc7d48da8Pharma Surgeen2026-07-27T00:00:00.000ZEffects of aged black garlic (ABG10+®) on lipoprotein subclass composition in Grade I hypertension: a randomized, triple-blind controlled trial with sex-stratified sequential allocationhttps://www.pharmaradar360.com/article/from-clinical-phenotypes-to-molecular-precision-multimodal-biomarkers-for-progre-2c7255af82c8fcfePharma Surgeen2026-07-27T00:00:00.000ZFrom clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsyhttps://www.pharmaradar360.com/article/macrohormones-in-endocrinology-prevalence-clinical-impact-and-diagnostic-approac-f4b14036f36f0590Pharma Surgeen2026-07-27T00:00:00.000ZMacrohormones in endocrinology: prevalence, clinical impact, and diagnostic approacheshttps://www.pharmaradar360.com/article/dapagliflozin-restores-nrf2-associated-antioxidant-signaling-and-mitochondrial-m-6a99bff88bf930fcPharma Surgeen2026-07-27T00:00:00.000ZDapagliflozin Restores NRF2-Associated Antioxidant Signaling and Mitochondrial Maintenance Markers in Doxorubicin-Challenged H9C2 Cardiomyoblasts: An In Vitro Mechanistic Studyhttps://www.pharmaradar360.com/article/e16541bdc15befacPharma Surgeen2026-07-27T00:00:00.000ZИзменение клинических показателей у пациентов с сухой формой возрастной дистрофии макулыhttps://www.pharmaradar360.com/article/1f2c91fd480c771aPharma Surgeen2026-07-27T00:00:00.000ZИммунокорригирующее действие препарата амиксин у больных увеальной меланомой в процессе комбинированного органосохраняющего леченияhttps://www.pharmaradar360.com/article/from-hansch-to-diffusion-models-data-algorithms-and-the-uneven-progress-of-compu-e66fcc0247bc3951Pharma Surgeen2026-07-27T00:00:00.000ZFrom Hansch to Diffusion Models: Data, Algorithms, and the Uneven Progress of Computational Drug Discoveryhttps://www.pharmaradar360.com/article/the-gut-brain-axis-and-anxiety-disorders-a-review-of-clinical-and-psychological-11fcfac212234a4cPharma Surgeen2026-07-27T00:00:00.000ZThe Gut-Brain Axis and Anxiety Disorders: A Review of Clinical and Psychological Perspectiveshttps://www.pharmaradar360.com/article/the-effect-of-dietary-fiber-based-on-fermentability-and-viscosity-on-the-gut-mic-2d07230a27aa578cPharma Surgeen2026-07-27T00:00:00.000ZThe effect of dietary fiber based on fermentability and viscosity on the gut microbiome composition in chronic kidney disease: a systematic review of experimental and clinical trialshttps://www.pharmaradar360.com/article/automated-modeling-of-population-pharmacokinetic-models-using-nlmixr2auto-a-clin-5894f4bdf4fda911Pharma Surgeen2026-07-27T00:00:00.000ZAutomated modeling of population pharmacokinetic models using nlmixr2auto: a clinical trial and real-world data studyhttps://www.pharmaradar360.com/article/past-month-nicotine-versus-thc-e-cigarette-use-and-moderate-to-severe-anxiety-sy-431cd6a1e034d278Pharma Surgeen2026-07-27T00:00:00.000ZPast-Month Nicotine versus THC E-Cigarette Use and Moderate-to-Severe Anxiety Symptoms Among U.S. Adults: A Cross-Sectional Analysis of the 2024 National Survey on Drug Use and Healthhttps://www.pharmaradar360.com/article/machine-learning-based-identification-of-drug-resistant-pathogen-infection-in-pa-e13ef99d5cd2e945Pharma Surgeen2026-07-27T00:00:00.000ZMachine Learning–Based Identification of Drug-Resistant Pathogen Infection in Patients With Sepsis: A Multicenter Cohort Studyhttps://www.pharmaradar360.com/article/clinical-decision-making-approach-and-associated-factors-among-nurses-working-in-7c369fc3bc5ebaa3Pharma Surgeen2026-07-27T00:00:00.000ZClinical Decision Making approach and Associated Factors among Nurses Working in South West Shoa Zone Hospitals Oromia Regional State, Ethiopia, 2023: A cross-sectional studyhttps://www.pharmaradar360.com/article/an-epithelial-mesenchymal-transition-related-gene-signature-predicts-prognosis-i-452b8eb8d7cb8035Pharma Surgeen2026-07-27T00:00:00.000ZAn epithelial-mesenchymal transition-related gene signature predicts prognosis, immune infiltration, and drug sensitivity in colorectal cancerhttps://www.pharmaradar360.com/article/importance-and-barriers-to-hepatitis-a-immunization-and-the-clinical-relevance-o-173fdefe46652c9aPharma Surgeen2026-07-27T00:00:00.000ZImportance and barriers to hepatitis A immunization and the clinical relevance of inactivated hepatitis A vaccine (TZ84 strain): insights from the pediatric expertshttps://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-snakebites-in-children-a-retrospective-study-fro-a0129d1316553fc0Pharma Surgeen2026-07-27T00:00:00.000ZClinical profile and outcome of snakebites in children: a retrospective study from a tertiary hospital in North-East Nigeriahttps://www.pharmaradar360.com/article/magnetic-targeting-systems-for-cancer-therapy-bridging-magnet-design-advanced-th-c859edaebf689a25Pharma Surgeen2026-07-27T00:00:00.000ZMagnetic targeting systems for cancer therapy: bridging magnet design, advanced therapeutics, and clinical translationhttps://www.pharmaradar360.com/article/translational-laboratory-medicine-and-interdisciplinary-biomarker-discovery-in-s-968dc022b15cbc38Pharma Surgeen2026-07-27T00:00:00.000ZTranslational laboratory medicine and interdisciplinary biomarker discovery in sepsis: bridging molecular insights and clinical decision-makinghttps://www.pharmaradar360.com/article/risk-outcome-assessment-with-novel-long-t-itc-complex-and-high-sensitivity-tropo-baf27a3c0c9a910cPharma Surgeen2026-07-27T00:00:00.000ZRisk outcome assessment with novel long-T ITC complex and high sensitivity troponin I and T in patients with suspected acute coronary syndromes: MERITnI substudyhttps://www.pharmaradar360.com/article/solvent-matters-a-call-for-rigorous-consideration-of-organic-co-solvents-in-drug-d81503ad02fac344Pharma Surgeen2026-07-27T00:00:00.000ZSolvent Matters: A Call for Rigorous Consideration of Organic Co-solvents in Drug-target Interaction Studieshttps://www.pharmaradar360.com/article/concurrent-triple-parasitic-infection-ctenocephalides-canis-rhipicephalus-sangui-7aeef9a708907adbPharma Surgeen2026-07-27T00:00:00.000ZConcurrent triple parasitic infection (Ctenocephalides canis, Rhipicephalus sanguineus, and Toxocara canis) in a domestic dog from Bangladesh: clinical management and zoonotic implicationshttps://www.pharmaradar360.com/article/effects-of-reflection-through-action-on-collaborative-clinical-reasoning-skills-50a5b1d4f2ddc0f3Pharma Surgeen2026-07-27T00:00:00.000ZEffects of reflection-through-action on collaborative clinical reasoning skills in an emergency dental simulationhttps://www.pharmaradar360.com/article/perspectives-of-turkish-family-physicians-in-istanbul-about-e-cigarettes-as-smok-09be4eb1e3e749a9Pharma Surgeen2026-07-27T00:00:00.000ZPerspectives of Turkish family physicians in Istanbul about e-cigarettes as smoking cessation aids: a cross-sectional survey studyhttps://www.pharmaradar360.com/article/sample-size-assumptions-timing-asymmetries-and-endpoint-selection-limit-the-inte-6f46780006974db8Pharma Surgeen2026-07-27T00:00:00.000ZSample size assumptions, timing asymmetries, and endpoint selection limit the interpretability of the CLEANSE hemoadsorption trial in septic shockhttps://www.pharmaradar360.com/article/ai-integrated-nanomaterial-based-biosensors-for-biomedical-diagnostics-engineeri-a09efa867f015986Pharma Surgeen2026-07-27T00:00:00.000ZAI-integrated nanomaterial-based biosensors for biomedical diagnostics: engineering design, signal processing, and clinical translationhttps://www.pharmaradar360.com/article/minocycline-for-acute-basilar-artery-occlusion-stroke-undergoing-endovascular-tr-6859cce6e429787fPharma Surgeen2026-07-27T00:00:00.000ZMinocycline for acute basilar artery occlusion stroke undergoing endovascular treatment: a randomized, evaluator-blinded, open-label, pilot trialhttps://www.pharmaradar360.com/article/exploring-palliative-care-clinical-skills-and-practice-capability-among-rural-al-53a6627a330bd105Pharma Surgeen2026-07-27T00:00:00.000ZExploring palliative care clinical skills and practice capability among rural allied health professionals: a learning needs analysishttps://www.pharmaradar360.com/article/clinical-and-pathological-characteristics-immune-microenvironment-and-survival-a-c357a043fcbe6e10Pharma Surgeen2026-07-27T00:00:00.000ZClinical and pathological characteristics, immune microenvironment, and survival analysis of molecular subtypes of surgically resected small cell lung cancerhttps://www.pharmaradar360.com/article/the-convergence-trial-protocol-a-phase-ii-iii-trial-for-conversion-surgery-for-g-6e803c5e07a26adfPharma Surgeen2026-07-27T00:00:00.000ZThe CONVERGENCE trial protocol: a phase II/III trial for conversion surgery for gastric cancer with peritoneal metastaseshttps://www.pharmaradar360.com/article/influencing-factors-and-individualized-intervention-strategies-for-inadequate-bo-6f13f0b36e564db3Pharma Surgeen2026-07-27T00:00:00.000ZInfluencing factors and individualized intervention strategies for inadequate bowel preparation before colonoscopy in high-risk populations: a review based on the clinical practice of painless colonoscopy in Chinahttps://www.pharmaradar360.com/article/national-trends-in-cardiovascular-deaths-with-concurrent-accidental-drug-poisoni-315735283f6f6281Pharma Surgeen2026-07-27T00:00:00.000ZNational trends in cardiovascular deaths with concurrent accidental drug poisoning coding in the United States: a 22-year analysis of the CDC WONDER database (1999–2020)https://www.pharmaradar360.com/article/convergence-of-ancient-wisdom-and-modern-healing-the-synergistic-potential-of-yo-87e71f4292ad6ae2Pharma Surgeen2026-07-27T00:00:00.000ZConvergence of Ancient Wisdom and Modern Healing: The Synergistic Potential of Yoga and Ayurveda in Contemporary Evidence-based Medicinehttps://www.pharmaradar360.com/article/a-comparative-performance-evaluation-of-the-vidas-cytomegalovirus-cmv-interferon-fd5d602b15698258Pharma Surgeen2026-07-27T00:00:00.000ZA comparative performance evaluation of the VIDAS cytomegalovirus (CMV) interferon-gamma release assay (IGRA) and T-SPOT CMV for measuring CMV-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients receiving letermovir prophylaxishttps://www.pharmaradar360.com/article/what-is-your-diagnosis-cervical-mass-in-a-timber-rattlesnake-8ac84827f70fd2b9Pharma Surgeen2026-07-27T00:00:00.000ZWhat Is Your Diagnosis? Cervical Mass in a Timber Rattlesnakehttps://www.pharmaradar360.com/article/clinical-and-sociodemographic-characteristics-of-young-people-with-early-psychos-4b82c3e96f9b405ePharma Surgeen2026-07-27T00:00:00.000ZClinical and Sociodemographic Characteristics of Young People With Early Psychosis: Comparing Cannabis Users and Non‐Users in a Specialized Early Intervention Settinghttps://www.pharmaradar360.com/article/evaluating-ai-demand-forecasting-models-for-manufacturing-planning-in-the-pharma-881cfd2d9c7c0e90Pharma Surgeen2026-07-27T00:00:00.000ZEvaluating AI demand forecasting models for manufacturing planning in the pharmaceutical sector using AHP and TOPSIS: evidence from literature and a Moroccan case studyhttps://www.pharmaradar360.com/article/rapid-reinitiation-of-clozapine-after-recent-discontinuation-3e2e3d794458a6dfPharma Surgeen2026-07-27T00:00:00.000ZRapid Reinitiation of Clozapine After Recent Discontinuationhttps://www.pharmaradar360.com/article/predicting-metabolic-adverse-effects-of-lithium-in-bipolar-disorder-b64129ba54d193bePharma Surgeen2026-07-27T00:00:00.000ZPredicting Metabolic Adverse Effects of Lithium in Bipolar Disorderhttps://www.pharmaradar360.com/article/impact-of-system-efficiency-on-out-of-hospital-cardiac-arrest-outcomes-and-hospi-55f5d57325cd0bbbPharma Surgeen2026-07-27T00:00:00.000ZImpact of system efficiency on out-of-hospital cardiac arrest outcomes and hospital stay: an observational study from Lombardia CARehttps://www.pharmaradar360.com/article/lower-stemi-mortality-at-high-volume-tertiary-centre-insights-from-a-compact-mul-51acff50c051d163Pharma Surgeen2026-07-27T00:00:00.000ZLower STEMI mortality at high volume tertiary centre: Insights from a compact multi-centre regionhttps://www.pharmaradar360.com/article/keeping-it-under-control-developing-reference-materials-during-a-rapidly-evolvin-f82474d220120328Pharma Surgeen2026-07-27T00:00:00.000ZKeeping It under Control: Developing Reference Materials during a Rapidly Evolving Arboviral Outbreakhttps://www.pharmaradar360.com/article/clinical-characteristics-of-alk-positive-nsclc-patients-treated-with-sequential-9ec8cabe0951b9f3Pharma Surgeen2026-07-27T00:00:00.000ZClinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centrehttps://www.pharmaradar360.com/article/profiling-the-pattern-of-medication-use-during-pregnancy-an-international-scopin-a44a6d2de5a98f04Pharma Surgeen2026-07-27T00:00:00.000ZProfiling the pattern of medication use during pregnancy: an international scoping review of observational studieshttps://www.pharmaradar360.com/article/temporal-mismatch-in-allogeneic-ipsc-therapies-biological-risks-and-implications-81d8f861410c63ffPharma Surgeen2026-07-27T00:00:00.000ZTemporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translationhttps://www.pharmaradar360.com/article/real-world-treatment-patterns-and-clinical-outcomes-among-patients-with-relapsed-992a6fa281e8722fPharma Surgeen2026-07-27T00:00:00.000ZReal-world treatment patterns and clinical outcomes among patients with relapsed/refractory multiple myeloma initiating their second, third, and fourth lines of treatment: data from the US Flatiron databasehttps://www.pharmaradar360.com/article/a-whole-word-computational-algorithm-for-phonological-error-scoring-differentiat-5970a5ca473159dfPharma Surgeen2026-07-27T00:00:00.000ZA whole-word computational algorithm for phonological error scoring: Differentiating children with developmental language disorder, hearing impairment, and typical developmenthttps://www.pharmaradar360.com/article/effectiveness-of-liquorice-gel-as-an-adjunct-to-non-surgical-periodontal-therapy-68ebd34172bb6ce4Pharma Surgeen2026-07-27T00:00:00.000ZEffectiveness of liquorice gel as an adjunct to non-surgical periodontal therapy in chronic periodontitis: a randomized controlled, clinical and microbiological trialhttps://www.pharmaradar360.com/article/effect-of-massed-versus-distributed-preclinical-training-on-subgingival-instrume-451e1dfe6b4fbbaaPharma Surgeen2026-07-27T00:00:00.000ZEffect of massed versus distributed preclinical training on subgingival instrumentation skill across the preclinical-to-clinical transitionhttps://www.pharmaradar360.com/article/supplemental-material-for-large-language-model-applications-for-real-time-clinic-12c78f0a97a8b887Pharma Surgeen2026-07-27T00:00:00.000ZSupplemental Material for Large Language Model Applications for Real-Time Clinical Mental Health Assessment: Current Potential and Future Directionshttps://www.pharmaradar360.com/article/intravenous-aprepitant-for-prevention-of-postoperative-nausea-and-vomiting-in-ad-a6f08015f254c157Pharma Surgeen2026-07-27T00:00:00.000ZIntravenous aprepitant for prevention of postoperative nausea and vomiting in adults at moderate-to-high risk in China: a multicenter, randomized, double-blind, placebo-controlled trialhttps://www.pharmaradar360.com/article/therapeutic-potential-of-commiphora-species-in-wound-healing-a-systematic-review-948c84a485cb79f2Pharma Surgeen2026-07-27T00:00:00.000ZTherapeutic Potential of Commiphora Species in Wound Healing: A Systematic Review of Clinical Evidencehttps://www.pharmaradar360.com/article/correction-the-bidirectionality-of-lawyer-reporting-bias-in-disproportionality-a-a42baa76f0331733Pharma Surgeen2026-07-27T00:00:00.000ZCorrection: The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysishttps://www.pharmaradar360.com/article/physiologically-based-pharmacokinetic-modeling-of-vedolizumab-in-healthy-adults-2ea879e711ffa2b8Pharma Surgeen2026-07-27T00:00:00.000ZPhysiologically Based Pharmacokinetic Modeling of Vedolizumab in Healthy Adults and Patients with Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/mr-107a-02-in-acute-postoperative-pain-management-following-bunionectomy-results-7df2241360de088dPharma Surgeen2026-07-27T00:00:00.000ZMR-107A-02 in Acute Postoperative Pain Management Following Bunionectomy: Results from a Multicenter, Placebo- and Active-Controlled, Phase 3 Trialhttps://www.pharmaradar360.com/article/comparison-of-induction-chemotherapy-followed-by-concurrent-chemoradiotherapy-ve-dcc2387022d04cabPharma Surgeen2026-07-27T00:00:00.000ZComparison of induction chemotherapy followed by concurrent chemoradiotherapy versus neoadjuvant chemotherapy followed by surgery and (chemo)radiotherapy in locoregionally advanced hypopharyngeal carcinoma: a prospective cohort studyhttps://www.pharmaradar360.com/article/clinical-and-radiographic-outcomes-of-rosa-robotic-assisted-total-knee-arthropla-377c27bc280518dcPharma Surgeen2026-07-27T00:00:00.000ZClinical and radiographic outcomes of ROSA robotic-assisted total knee arthroplasty: a retrospective comparison of anatomic (persona) versus symmetric (vanguard) implant designshttps://www.pharmaradar360.com/article/biofilm-disruption-by-citronellol-and-geraniol-against-clinical-uropathogenic-ps-27dfc60d36b2df6bPharma Surgeen2026-07-27T00:00:00.000ZBiofilm disruption by citronellol and geraniol against clinical uropathogenic Pseudomonas aeruginosa: an integrated in vitro and in silico investigationhttps://www.pharmaradar360.com/article/germline-pathogenic-variants-in-japanese-adolescents-and-young-adults-with-advan-38e95c6d044ba808Pharma Surgeen2026-07-27T00:00:00.000ZGermline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor–normal paired sequencing studyhttps://www.pharmaradar360.com/article/letter-to-the-editor-a-kaleidoscopic-autoimmune-syndrome-covas-following-covid-1-d1a08099171925c3Pharma Surgeen2026-07-27T00:00:00.000ZLetter to the Editor: “A kaleidoscopic autoimmune syndrome (COVAS) following COVID-19 exposure”https://www.pharmaradar360.com/article/evaluation-of-serum-chromium-nickel-and-magnesium-levels-in-patients-with-type-2-cd111f238efb3a6bPharma Surgeen2026-07-27T00:00:00.000ZEvaluation of serum chromium, nickel, and magnesium levels in patients with type 2 diabetes mellitus and periodontitis: A cross-sectional studyhttps://www.pharmaradar360.com/article/technique-dependent-differences-in-internal-adaptation-porosity-and-degree-of-co-b030e2831c6b0edaPharma Surgeen2026-07-27T00:00:00.000ZTechnique-dependent differences in internal adaptation, porosity and degree of conversion of short fibre-reinforced composite restorations in deep MOD cavitieshttps://www.pharmaradar360.com/article/skin-keratin-correlates-with-bone-and-tendon-collagen-quality-a-proof-of-concept-76be41121023a713Pharma Surgeen2026-07-27T00:00:00.000ZSkin keratin correlates with bone and tendon collagen quality: a proof-of-concept clinical study using FTIR spectroscopy in shoulder arthroplasty patientshttps://www.pharmaradar360.com/article/the-pivotal-role-of-macrophages-in-tumorigenesis-and-pioneering-cancer-immunothe-0121b60a1472778fPharma Surgeen2026-07-27T00:00:00.000ZThe pivotal role of macrophages in tumorigenesis and pioneering cancer immunotherapy across pre-clinical and clinical frontiershttps://www.pharmaradar360.com/article/molecular-plasticity-of-lama3-across-the-disease-spectrum-pathogenic-mechanisms-aa60ffb704795e6ePharma Surgeen2026-07-27T00:00:00.000ZMolecular plasticity of LAMA3 across the disease spectrum: pathogenic mechanisms and clinical translationhttps://www.pharmaradar360.com/article/age-sex-and-segment-specific-myocardial-t1-and-t2-reference-values-in-a-healthy-026edf9b8016739bPharma Surgeen2026-07-27T00:00:00.000ZAge-, sex-, and segment-specific myocardial T1 and T2 reference values in a healthy cohort: a prospective single-center studyhttps://www.pharmaradar360.com/article/suizidalitat-mit-instrumentellen-anteilen-bei-stationarer-psychiatrischer-aufnah-44a8325d8233098aPharma Surgeen2026-07-27T00:00:00.000ZSuizidalität mit instrumentellen Anteilen bei stationärer psychiatrischer Aufnahme oder Entlassung: klinische, ethische und juristische Implikationen sowie Handlungsempfehlungenhttps://www.pharmaradar360.com/article/emerging-trends-in-artificial-intelligence-driven-drug-discovery-balancing-chemi-ecb9817948defcd5Pharma Surgeen2026-07-27T00:00:00.000ZEmerging Trends in Artificial Intelligence‐Driven Drug Discovery: Balancing Chemical Design and Pharmacological Properties for Cancer Therapyhttps://www.pharmaradar360.com/article/successful-co-administration-of-secukinumab-and-dupilumab-in-a-patient-with-psor-309122d66c0b8fe9Pharma Surgeen2026-07-27T00:00:00.000ZSuccessful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitishttps://www.pharmaradar360.com/article/fitness-to-stand-trial-in-india-demographic-clinical-and-legal-profiles-of-court-189ef1962952c886Pharma Surgeen2026-07-27T00:00:00.000ZFitness to Stand Trial in India: Demographic, Clinical, and Legal Profiles of Court‐Referred Defendantshttps://www.pharmaradar360.com/article/preparation-and-characterization-of-scp-ph-scp-responsive-kaolin-containing-pect-b2c940c5ef1dcaf6Pharma Surgeen2026-07-27T00:00:00.000ZPreparation and Characterization of <scp>pH</scp> ‐Responsive Kaolin‐Containing Pectin/Poly(Acrylic Acid) <scp>IPN</scp> Hydrogel for Potential Colon‐Targeted Drug Deliveryhttps://www.pharmaradar360.com/article/world-health-organization-multimodal-improvement-strategy-for-hand-hygiene-9f938c60f4890c09Pharma Surgeen2026-07-27T00:00:00.000ZWorld Health Organization Multimodal Improvement Strategy for Hand Hygienehttps://www.pharmaradar360.com/article/nct07729696-digital-psychoeducational-intervention-for-young-adults-with-fertili-49b7b61dd0b1a172Pharma Surgeen2026-07-27T00:00:00.000ZNCT07729696: Digital Psychoeducational Intervention for Young Adults With Fertility Related Distress Following Cancer Diagnosishttps://www.pharmaradar360.com/article/nct07729514-effect-of-different-hyaluronic-acids-in-the-treatment-of-subdeltoid-de0be8bc1c60be11Pharma Surgeen2026-07-27T00:00:00.000ZNCT07729514: Effect of Different Hyaluronic Acids in the Treatment of Subdeltoid Bursitishttps://www.pharmaradar360.com/article/nct07729020-effectiveness-of-virtual-reality-in-reducing-anxiety-and-pain-during-5ec428af8a684fd0Pharma Surgeen2026-07-27T00:00:00.000ZNCT07729020: Effectiveness of Virtual Reality in Reducing Anxiety and Pain During the First Postoperative Orthopedic Dressing Change in Pediatric Patientshttps://www.pharmaradar360.com/article/nct07728890-effect-of-box-breathing-exercise-on-anxiety-pain-and-pulmonary-funct-c8d0ad2a7d947b9cPharma Surgeen2026-07-27T00:00:00.000ZNCT07728890: Effect of Box Breathing Exercise on Anxiety, Pain, and Pulmonary Function Tests in Patients Undergoing Colonoscopyhttps://www.pharmaradar360.com/article/nct07728669-digital-dietary-intervention-for-patients-receiving-glp-1-receptor-a-d2913540b3640819Pharma Surgeen2026-07-27T00:00:00.000ZNCT07728669: Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapyhttps://www.pharmaradar360.com/article/nct07728643-endothelial-extracellular-vesicles-as-biomarkers-of-endothelial-acti-be5d18b151b7aae8Pharma Surgeen2026-07-27T00:00:00.000ZNCT07728643: Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Children With Newly Diagnosed Hypertensionhttps://www.pharmaradar360.com/article/nct07728318-efficacy-safety-and-treatment-satisfaction-of-once-weekly-tirzepatid-700c86007750cc9cPharma Surgeen2026-07-27T00:00:00.000ZNCT07728318: Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patientshttps://www.pharmaradar360.com/article/nct07728188-a-study-to-evaluate-adverse-events-and-change-in-disease-activity-wi-2694e3d9bbb1c926Pharma Surgeen2026-07-27T00:00:00.000ZNCT07728188: A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct07728136-ai-guided-mechanical-ventilation-in-children-a-randomized-controlled-c8018939ea36adf6Pharma Surgeen2026-07-27T00:00:00.000ZNCT07728136: AI-Guided Mechanical Ventilation in Children: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07728019-efficacy-and-safety-of-retlirafusp-alfa-plus-bevacizumab-and-chemoth-eae518e961e52a47Pharma Surgeen2026-07-27T00:00:00.000ZNCT07728019: Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLMhttps://www.pharmaradar360.com/article/nct07727902-functional-inspiratory-muscle-training-for-gait-recovery-in-patients-99806dfd16232521Pharma Surgeen2026-07-27T00:00:00.000ZNCT07727902: Functional Inspiratory Muscle Training for Gait Recovery in Patients With Chronic Strokehttps://www.pharmaradar360.com/article/nct07727642-optimization-of-antiretroviral-therapy-in-patients-with-aids-related-41398957ca24519fPharma Surgeen2026-07-27T00:00:00.000ZNCT07727642: Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphomahttps://www.pharmaradar360.com/article/nct07727174-a-clinical-trial-evaluating-the-influence-of-the-ingredients-mycondr-551860c63fbbb29aPharma Surgeen2026-07-27T00:00:00.000ZNCT07727174: A Clinical Trial Evaluating the Influence of the Ingredients MyCondro™ and Bovine Chondroitin Sulfate on the Behavior of Cells in the Osteoarticular Spherehttps://www.pharmaradar360.com/article/nct07725939-a-study-of-24-to-52-weeks-treatment-to-evaluate-the-efficacy-and-saf-9996ea74e6510319Pharma Surgeen2026-07-27T00:00:00.000ZNCT07725939: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitishttps://www.pharmaradar360.com/article/nct07725926-integrating-exposure-and-response-prevention-and-habit-reversal-tech-7cc8cd92ffd9aa10Pharma Surgeen2026-07-27T00:00:00.000ZNCT07725926: Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of Obsessive-Compulsive Disorder (Tourettic OCD)https://www.pharmaradar360.com/article/nct07724457-testing-the-addition-of-a-new-anti-cancer-drug-glofitamab-to-usual-c-f7142c6f64b9943dPharma Surgeen2026-07-27T00:00:00.000ZNCT07724457: Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphomahttps://www.pharmaradar360.com/article/nct07662148-a-study-to-learn-more-about-the-safety-of-a-single-dose-of-biib144-a-9327d1b106792b43Pharma Surgeen2026-07-27T00:00:00.000ZNCT07662148: A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebohttps://www.pharmaradar360.com/article/nct07650799-ai-assisted-rare-disease-diagnosis-baba422575fc1faePharma Surgeen2026-07-27T00:00:00.000ZNCT07650799: AI-assisted Rare Disease Diagnosishttps://www.pharmaradar360.com/article/nct07619534-collection-of-csf-samples-from-participants-with-metastatic-triple-n-499b6b2cc3691899Pharma Surgeen2026-07-27T00:00:00.000ZNCT07619534: Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases